[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Praxis Precision Medicines\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":206},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,78,103,134,158,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100594475","phase-3-a-clinical-trial-of-elsunersen-in-pediatric-scn2a-dee-to-assess-efficacy-and-safety-100594475",false,"NCT07019922","A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety","A Multi-Center, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy","Inclusion Criteria:\n\n* Has a documented Gain of Function SCN2A variant confirmed through genetic testing.\n* Has onset of seizures prior to 3 months of age.\n* Seizure frequency of 4 or more countable motor seizures per 28-day during the Baseline Observation Period.\n\nExclusion Criteria:\n\n* Has any clinically significant or known pathogenic genetic variant other than in the SCN2A gene, or a genetic variant that may explain or contribute to the participant's epilepsy and\u002For developmental disorder.\n* Has bone, spine (eg, kyphosis, scoliosis), bleeding, or other disorder.\n* Has received any experimental or investigational drug, device, or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, including any prior use of gene therapy.\n* Is currently pregnant or breastfeeding or is planning to become pregnant during the clinical trial.","ALL","1 Day","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","A Multi-Center, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy",[27,28],"Epileptic Encephalopathy","SCN2A Encephalopathy",[30,31,32,33,34,35],"epilepsis","early onset scn2a","epileptic encephalopathy","scn2a","gain of function","seizure","RECRUITING","2026-05-22",{"date":39,"type":40},"2026-05-27","ACTUAL",{"date":42,"type":40},"2025-08-13",{"date":44,"type":21},"2028-12",{"name":46,"class":47},"Praxis Precision Medicines","INDUSTRY",10,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100593748","phase-3-a-clinical-trial-for-participants-with-dee-to-assess-efficacy-safety-tolerability-and-pk-of-relutrigine-100593748","NCT07010471","A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine","A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants With DEE Followed by an Open-Label Extension","EMERALD","Inclusion Criteria:\n\n* Has a documented diagnosis of a developmental and epileptic encephalopathy.\n* Onset of seizures \\\u003C12 years old.\n* Has a weight \\>7 kg at the time of signing consent\u002Fassent.\n\nExclusion Criteria:\n\n* Has a history of left bundle branch block, arrhythmias, Brugada syndrome, congenital heart disease, familial short QT syndrome, or family history of sudden death or ventricular arrhythmias, including idiopathic ventricular fibrillation.\n* Had 2 or more episodes of convulsive status epilepticus requiring hospitalization and intubation in the 6 months prior to Screening.\n* Has an abnormal ECG reading, including a QT interval corrected for heart rate using Bazett's method (QTcB) \\\u003C350 and \\>450 ms (males), or \\\u003C360 and \\>460 ms (females) at Screening and\u002For on Day 1.\n* Any nerve stimulation must have been placed at least 3 months prior to Screening with at least 1 month of stable settings prior to Screening.\n* Has received any other experimental or investigational drug, device, or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, including any prior use of gene therapy.\n* Is currently pregnant or breastfeeding or is planning to become pregnant during the clinical trial or within 5 half-lives of the last study drug dose.","2 Years","65 Years",{"count":60,"type":21},160,[24],"A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension",[64],"Developmental and Epileptic Encephalopathy 1",[66,67,68],"DEE","Developmental and Epileptic Encephalopathy","epilepsy","2026-05-08",{"date":71,"type":40},"2026-05-11",{"date":73,"type":40},"2025-07-09",{"date":75,"type":21},"2027-11",{"name":46,"class":47},11,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":5},"100631770","phase-3-double-blind-randomized-clinical-trial-evaluating-the-efficacy-and-safety-of-vormatrigine-in-adults-with-focal-seizures-100631770","NCT07505004","Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures","A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures","POWER2","Inclusion Criteria:\n\n* Has a diagnosis of focal onset epilepsy according to the International League Against Epilepsy Classification of Epilepsy (2017).\n* Prior to randomization, past evidence by CT or MRI that has ruled out a progressive cause of epilepsy in the judgement of the investigator and\u002For in consultation with the medical monitor.\n* Participant must attest to be taking stable doses of 1 or up to 3 acceptable ASMs for at least 4 weeks prior to screening and during screening prior to Day 1.\n* Has at least 4 countable focal onset seizures during the 4 weeks of Observation Period immediately prior to randomization with no more than 21 days seizure free during this period.\n* Seizure diary must be completed for ≥80% days in the Observation Period.\n\nExclusion Criteria:\n\n* Participant has had any of the following within the 12-month period preceding trial entry:\n\n  1. evidence of experiencing pseudo or psychogenic seizures\n  2. cluster seizures where the individual seizures cannot be counted\n  3. an episode of convulsive status epilepticus requiring hospitalization and intubation\n  4. seizures secondary to illicit drug or alcohol use\n* Seizures secondary to ongoing infection, neoplasia, demyelinating disease, progressive degenerative disease, metabolic illness deemed progressive, progressive structural lesion or encephalopathy.\n* Previously documented EEG which shows any pattern not consistent with focal etiology of seizures.\n* Planned epilepsy surgery during the course of the clinical trial.\n* History of any of the following:\n\n  1. neurosurgery for seizures \\\u003C1 year prior to enrollment\n  2. radiosurgery \\\u003C2 years prior to enrollment\n  3. neurostimulator placed \\\u003C1 year prior to Screening\n  4. neurostimulator placed \\>1 year prior to Screening but settings have not been stable for at least 2 months prior to Screening\n* Active suicidal plan\u002Fintent in the past 6 months, or a history of suicide attempt in the last 2 years, or more than 1 lifetime suicide attempt, as confirmed by C-SSRS.\n* Has any significant ongoing disease, disorder, laboratory abnormalities, alcohol or drug abuse or dependence, environmental factor, or ongoing or recent history of any psychiatric, medical, or surgical condition.\n* Participants with a history of malignancy, myeloproliferative or lymphoproliferative disorders within the past 3 years are excluded.\n* History or presence of uncontrolled cardiac diseases including conduction and structural abnormalities.\n* Total bilirubin value \\>1.5×ULN; an ALT or AST value \\>3×ULN.\n* History of or active HIV infection or positive screening result for: HIV 1 or 2 antibodies. Evidence of active hepatitis B or hepatitis C infection, as determined by relevant screening assessments.\n* Has received any other experimental or investigational drug, device or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, or any prior use of gene or cell therapy.\n* Vigabatrin: Use in the last 5 years without stable visual fields tested twice over the 12 months after the last dose of vigabatrin.\n* Felbamate: If used as a concomitant ASM, patients must be on felbamate for at least 2 years, with a stable dose for 2 months prior to Screening. If a patient received felbamate in the past, it must have been discontinued 2 months prior to screening.\n* Significant allergic reaction to an ASM(s), including dermatological (e.g. Stevens-Johnson syndrome), hematological, or organ toxicity reactions. Severe reactions do not include simple maculopapular eruption and allergic rhinitis.\n* Is pregnant or breastfeeding at the time of Screening or has a positive serum pregnancy test at Screening or is planning to become pregnant during the clinical trial or prior to end of study visit.\n* Previous exposure to vormatrigine or known hypersensitivity to any component used in the vormatrigine formulation.","85 Years",{"count":88,"type":21},300,[24],"A multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)",[92],"Focal Epilepsy",[94],"focal epilepsy","2026-03-26",{"date":97,"type":40},"2026-04-01",{"date":99,"type":40},"2026-01-29",{"date":101,"type":21},"2027-05",{"name":46,"class":47},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":18,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":112,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},"100495944","phase-1-a-clinical-trial-of-prax-222-in-pediatric-participants-with-early-onset-scn2a-developmental-and-epileptic-encephalopathy-100495944","NCT05737784","A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy","A Seamless, Clinical Trial to Investigate the Safety and Efficacy of Multiple Doses of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy","Inclusion Criteria:\n\n* Has onset of seizures prior to 3 months of age.\n* Has a minimum weight of at least 10 kg at screening.\n* Has a documented SCN2A variant through genetic testing obtained via a laboratory accredited per Clinical Laboratory Improvement Amendments (CLIA) or College of American Pathologists (CAP) or equivalent.\n* Additional inclusion criteria apply and will be assessed by the study team\n\nExclusion Criteria:\n\n* Has any clinically significant or known pathogenic genetic variant other than in the SCN2A gene, or a genetic variant that may explain or contribute to the participant's epilepsy and\u002For developmental disorder.\n* Is taking more than 2 sodium channel blocking anti-seizure medications\n* Additional exclusion criteria apply and will be assessed by the study team",{"count":111,"type":21},60,[113,114],"PHASE1","PHASE2","The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.",[117,118],"SCN2A-DEE","Epilepsy",[120,121,122,123,124,67,66],"Antisense Oligonucleotide","NaV1.2 Voltage-Gated Sodium Channel","Voltage-Gated Sodium Channel Blockers","SCN2A variant","Pediatric epilepsy","2025-08-15",{"date":127,"type":40},"2025-08-21",{"date":129,"type":40},"2023-04-13",{"date":131,"type":21},"2027-09",{"name":46,"class":47},3,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":139,"conditions":146,"keywords":148,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":157},"100592935","phase-2-double-blind-randomized-trial-of-prax-628-in-adults-with-focal-seizures-to-evaluate-efficacy-and-safety-power1-100592935","NCT06999902","Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)","A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults With Focal Seizures (POWER1)","POWER1","Inclusion Criteria:\n\n1. A diagnosis of focal onset epilepsy according to the International League Against Epilepsy (ILAE) Classification of Epilepsy.\n2. Past evidence by computed tomography (CT) or magnetic resonance imaging (MRI) that has ruled out a progressive cause of epilepsy in the judgement of the investigator and\u002For in consultation with the medical monitor.\n\nExclusion Criteria:\n\n1. Subject has had any of the of the following within the 12-month period preceding trial entry: History of pseudo or psychogenic seizures, cluster seizures where the individual seizures cannot be counted, an episode of convulsive status epilepticus requiring hospitalization and intubation, or subject only has focal seizures with awareness that do not have motor activity.\n2. Planned epilepsy surgery during the course of the clinical trial.\n3. History of neurosurgery for seizures \\\u003C1 year prior to enrollment, or radiosurgery \\\u003C2 years prior to enrollment or vagus nerve stimulation (VNS) implantation.\n4. History of schizophrenia, obsessive-compulsive disorder, or other serious mental health disorders.\n5. History of malignancy, myeloproliferative or lymphoproliferative disorders within the past 5 years are excluded.\n6. History of cardiac disease(s)\u002Fcardiac conduction disorders\u002For cardiac structural abnormality(ies).\n7. Has a positive test result or a known history of a positive test result for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or anti-hepatitis C virus (HCV) antibody at Screening.\n8. Is pregnant or is breastfeeding at the time of Screening or has a positive serum pregnancy test at Screening or is planning to become pregnant during the clinical trial or within 14 days of the last study drug dose.\n9. Has received any other experimental or investigational drug, device or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, or any prior use of gene therapy.","75 Years",{"count":144,"type":21},230,[114,24],[147],"Focal Seizure",[147],"2025-05-23",{"date":151,"type":40},"2025-05-31",{"date":153,"type":40},"2024-12-11",{"date":155,"type":21},"2025-12-08",{"name":46,"class":47},26,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":142,"enrollmentInfo":165,"targetDuration":4,"studyType":22,"phases":167,"briefSummary":163,"conditions":168,"keywords":171,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":77},"100585898","phase-2-an-open-label-trial-to-evaluate-the-efficacy-and-safety-of-prax-628-in-adults-with-focal-onset-or-tonic-clonic-seizures-100585898","NCT06908356","An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures","An Open Label Clinical Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adult Patients With Focal Onset or Primary Generalized Tonic-Clonic Seizures","Inclusion Criteria:\n\n* A diagnosis of focal onset seizures or idiopathic generalized tonic clonic seizures.\n* Evidence by computed tomography (CT) or magnetic resonance imaging (MRI) in the past that has ruled out a progressive cause of epilepsy.\n* Participant must have been receiving stable doses of allowable ASMs (a minimum of 1 and a maximum of 3 ASMs).\n* Participant and\u002For caregiver (if applicable) self-reports at least 2 countable focal onset seizures per month for focal onset patients, or 1 countable generalized tonic-clonic seizure per month in the 3 months immediately prior to the Screening\u002FObservation Period for PGTCS patients.\n\nExclusion Criteria:\n\n* History of pseudo or psychogenic seizures, or cluster seizures only, within the 12-month period preceding study entry where the individual seizures cannot be counted, or an episode of convulsive status epilepticus requiring hospitalization and intubation in the 12 months prior to Screening.\n* Planned epilepsy surgery during the course of the clinical trial.\n* History of neurosurgery for seizures \\\u003C1 year prior to enrollment, or radiosurgery \\\u003C2 years prior to enrollment.\n* Schizophrenia and obsessive-compulsive disorder, or other serious mental health disorders.\n* Active suicidal plan\u002Fintent in the past 6 months, or a history of suicide attempt in the last 2 years, or more than 1 lifetime suicide attempt.\n* Participants with a history of malignancy, myeloproliferative or lymphoproliferative disorders within the past 5 years are excluded.\n* History of cardiac disease(s)\u002Fcardiac conduction disorders\u002For cardiac structural abnormality(ies).\n* Is pregnant or breastfeeding at the time of Screening, or has a positive serum pregnancy test at Screening or is planning to become pregnant during the clinical trial or within 14 days of the last study drug dose.\n* Has received any other experimental or investigational drug, device or other therapy within 30 days or 5 half-lives (whichever is longer) prior to Screening, or any prior use of gene therapy.\n* Vigabatrin: Use in the last 5 years without stable visual fields tested twice over the 12 months after the last dose of vigabatrin.\n* Felbamate: If used as a concomitant ASM, patients must be on felbamate for at least 2 years, with a stable dose for 2 months prior to Screening. If a patient received felbamate in the past, it must have been discontinued 2 months prior to Screening.",{"count":166,"type":21},50,[114],[169,170],"Focal Onset Seizure","Primary Generalized Epilepsy",[169,170,172],"Tonic-Clonic","2025-03-26",{"date":175,"type":40},"2025-04-03",{"date":177,"type":40},"2025-01-10",{"date":179,"type":21},"2025-07",{"name":46,"class":47},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":188,"sex":16,"minAge":18,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":22,"phases":192,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":196,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":205},"100580717","phase-1-a-clinical-trial-to-evaluate-the-relative-bioavailability-of-prax-628-100580717","NCT06840925","A Clinical Trial to Evaluate the Relative Bioavailability of PRAX-628","A Phase 1, Randomized, Open-Label, 2-Way Crossover Clinical Trial in Healthy Participants to Evaluate the Relative Bioavailability of PRAX-628 Tablet Formulation Compared to Capsule Formulation","Inclusion Criteria:\n\n* Weight of at least 50 kg with body mass index (BMI) between 18 and 32 kg\u002Fm2\n* Is in good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital signs measurements, and clinical laboratory evaluations\n* All females have a negative pregnancy test and are not planning to get pregnant for the duration of the trial\n* Female of non-childbearing potential by reason of surgery or at least 1 year post menopause\n* Additional inclusion criteria apply and will be assessed by the study team\n\nExclusion Criteria:\n\n* Any clinically significant abnormalities, medical, or psychiatric conditions identified by a detailed medical history, or physical examination\n* Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs. Examples of such conditions include (but are not limited to):\n\n  1. History of inflammatory bowel syndrome, gastritis, gastrointestinal or rectal bleeding\n  2. History of major gastrointestinal tract surgery (ie, gastrectomy, bowel resection, cholecystectomy etc.)\n  3. History or evidence of pancreatic injury or pancreatitis\n* History or presence of impaired renal function supported by estimated glomerular filtration rate \\[eGFR\\]\\\u003C60 mL\u002Fmin\u002F1.73m2 or clinically significant abnormal urinary constituents (eg, protein)\n* History of cancer except for nonmelanoma skin cancer resected \\>2 years ago and that has been definitively treated and considered cured.\n* History of any lifetime suicide attempt or active suicidal ideation with intent as indicated by a \"Yes\" response to either Question 4 or 5 on the C-SSRS \"Baseline\u002F Screening\" version\n* History of left bundle branch block, arrhythmias, Brugada syndrome, congenital heart disease, familial short QT syndrome, or family (first degree relative) history of sudden death, ventricular or clinically significant arrhythmias, including idiopathic ventricular fibrillation.\n* Abnormal standard 12-lead ECG after at least 5 minutes resting in the supine position\n* Abnormal vital signs after at least 5 minutes resting in the supine position:\n* Has any of the following: a serum total bilirubin value \\>1.1× the upper limit of normal (ULN), a serum alanine aminotransferase (ALT) value \\>1.5×ULN, or aspartate aminotransferase (AST) value \\>1.5×ULN\n* Serology test positive for human immunodeficiency virus (HIV), or hepatitis B or C\n* Known allergy or hypersensitivity to any component of the formulation of PRAX 628 or history of severe allergy or anaphylaxis to a drug, food, or other exposure\n* Use of any experimental or investigational drug or device within 30 days prior to the first dose of study drug or 5 times the terminal half-life of the drug, whichever is longer\n* Use of systemic prescription medications; or over-the-counter medication, including multivitamins; and dietary and herbal supplements within 2 weeks or 5 times the terminal half-life of the medication prior to the first dose of study drug (whichever is longer) and for the duration of the trial\n* Donation of blood within 1 month prior to Screening, plasma within 1 week prior to Screening, or platelets within 6 weeks prior to Screening\n* Any vaccination within 28 days of the first dose of study drug\n* Additional exclusion criteria apply and will be assessed by the study team",true,"55 Years",{"count":191,"type":21},16,[113],"A phase I clinical trial to evaluate the relative bioavailability of PRAX-628 tablet formulation compared to capsule formulation",[195],"Healthy","NOT_YET_RECRUITING","2025-02-18",{"date":199,"type":40},"2025-02-21",{"date":201,"type":21},"2025-03-24",{"date":203,"type":21},"2025-06-30",{"name":46,"class":47},1,""]